News & Updates
Filter by Specialty:

9-month, oral modified treatment regimens make the grade in drug-resistant TB
Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.
9-month, oral modified treatment regimens make the grade in drug-resistant TB
04 Jul 2024
NOTUS boosts dupilumab role for COPD, type 2 inflammation
The phase III NOTUS trial further validates the potential of the monoclonal antibody dupilumab in reducing exacerbations and improving lung function and quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.
NOTUS boosts dupilumab role for COPD, type 2 inflammation
04 Jul 2024
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O2 support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study
Risk of death 54 percent lower with remdesivir added for hospitalized COVID-19 patients on O₂ support
01 Jul 2024
Does lung biopsy worsen lung function, survival in IPF patients?
Surgical lung biopsy (SLB) neither reduces lung function nor increases the risk of death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF), reports a study.
Does lung biopsy worsen lung function, survival in IPF patients?
28 Jun 2024
KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.